CeriBell (NASDAQ:CBLL) CRO Joseph Manni Sells 1,361 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) CRO Joseph Manni sold 1,361 shares of the business’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $24.02, for a total transaction of $32,691.22. Following the completion of the transaction, the executive owned 55,956 shares of the company’s stock, valued at approximately $1,344,063.12. The trade was a 2.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

CeriBell Stock Up 0.0%

CBLL traded up $0.01 during trading on Tuesday, hitting $23.95. 243,381 shares of the company’s stock traded hands, compared to its average volume of 457,237. The stock has a market capitalization of $919.20 million, a price-to-earnings ratio of -13.61 and a beta of 0.81. The company’s 50 day simple moving average is $19.77 and its two-hundred day simple moving average is $19.27. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $25.33. The company has a current ratio of 9.18, a quick ratio of 8.79 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.04). The business had revenue of $28.10 million during the quarter, compared to analysts’ expectations of $27.28 million. CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. Analysts predict that CeriBell, Inc. will post -1.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. BTIG Research boosted their target price on CeriBell from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Weiss Ratings raised shares of CeriBell from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Barclays upgraded shares of CeriBell to a “neutral” rating in a research note on Tuesday, August 18th. Finally, Canaccord Genuity Group increased their price objective on shares of CeriBell from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.40.

Institutional Trading of CeriBell

A number of hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. lifted its holdings in CeriBell by 41.4% in the fourth quarter. Russell Investments Group Ltd. now owns 2,918 shares of the company’s stock valued at $64,000 after acquiring an additional 854 shares during the period. Sei Investments Co. boosted its position in CeriBell by 2.3% in the first quarter. Sei Investments Co. now owns 50,360 shares of the company’s stock worth $923,000 after purchasing an additional 1,125 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of CeriBell by 3,971.0% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock valued at $28,000 after purchasing an additional 1,231 shares during the period. Deutsche Bank AG increased its position in shares of CeriBell by 1.7% during the 4th quarter. Deutsche Bank AG now owns 85,182 shares of the company’s stock valued at $1,868,000 after purchasing an additional 1,393 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of CeriBell in the 1st quarter worth approximately $27,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.